Aligos Therapeutics (ALGS) Income towards Parent Company (2019 - 2026)

Aligos Therapeutics has reported Income towards Parent Company for 8 years, with the latest figure at -$23.0 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company fell 153.47% year-over-year to -$23.0 million; the trailing twelve-month figure through Mar 2026 stood at -$90.3 million (down 69.59% YoY), and the FY2025 full-year result was -$24.2 million, up 81.56% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$23.0 million, down from -$19.9 million in the prior quarter.
• The five-year high for Income towards Parent Company was $43.1 million in Q1 2025, with the low at -$82.1 million in Q4 2024.
• Historically, Income towards Parent Company has averaged -$21.3 million across 5 years, with a median of -$19.9 million in 2022.
• The largest YoY upside for Income towards Parent Company was 223.59% in 2025 against a maximum downside of 413.44% in 2025.
• Aligos Therapeutics' Income towards Parent Company stood at -$21.9 million in 2022, then retreated by 27.44% to -$27.9 million in 2023, then tumbled by 194.53% to -$82.1 million in 2024, then surged by 75.8% to -$19.9 million in 2025, then slipped by 15.89% to -$23.0 million in 2026.
• The last three Income towards Parent Company figures came in at -$23.0 million (Q1 2026), -$19.9 million (Q4 2025), and -$31.5 million (Q3 2025), per Business Quant data.